{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine+Therapy+1&page=2",
    "query": {
      "intervention": "Endocrine Therapy 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine+Therapy+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T17:48:57.385Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05837455",
      "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "VENTANA MIB-1 Ki67 assay",
          "type": "DEVICE"
        },
        {
          "name": "Oncotype DX® Recurrence Score",
          "type": "DEVICE"
        },
        {
          "name": "PAM50-based Prosigna breast cancer gene signature assay",
          "type": "DEVICE"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Combination anthracycline and/or taxane based treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2024-05-30",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05837455"
    },
    {
      "nct_id": "NCT05645536",
      "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TOL2506",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole tablets",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Exemestane Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolmar Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "18 Years to 51 Years"
      },
      "enrollment_count": 250,
      "start_date": "2022-12-28",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 17,
      "location_summary": "Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05645536"
    },
    {
      "nct_id": "NCT05926024",
      "title": "Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Exercise Recall Patient Reported Outcomes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes PROMIS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes FACT-Endocrine Symptoms",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes Penn Arthralgia Aging Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "p16 tumor suppressor gene",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 253,
      "start_date": "2023-01-06",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05926024"
    },
    {
      "nct_id": "NCT02102490",
      "title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2014-06-10",
      "completion_date": "2018-10-22",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 27,
      "location_summary": "Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02102490"
    },
    {
      "nct_id": "NCT07310901",
      "title": "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obese But Otherwise Healthy Participants"
      ],
      "interventions": [
        {
          "name": "CRB-913",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 252,
      "start_date": "2025-12-04",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07310901"
    },
    {
      "nct_id": "NCT00073281",
      "title": "Islet Transplantation for Patients With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Islet transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-08",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-15",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073281"
    },
    {
      "nct_id": "NCT06305286",
      "title": "Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2024-03-04",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305286"
    },
    {
      "nct_id": "NCT03531827",
      "title": "Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer",
        "Prostate Neoplasms"
      ],
      "interventions": [
        {
          "name": "enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "CRLX101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2019-03-26",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531827"
    },
    {
      "nct_id": "NCT00303134",
      "title": "Islet Cell Transplants for Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Islet Cell Transplantation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2003-08-01",
      "completion_date": "2010-06-24",
      "has_results": false,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303134"
    },
    {
      "nct_id": "NCT04692103",
      "title": "Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Positive",
        "Primary or Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "F-18 16 Alpha-Fluoroestradiol",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-07-10",
      "completion_date": "2041-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-26T17:48:57.385Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04692103"
    }
  ]
}